What is SRX Health Solutions Inc's earnings per share (EPS)?

SRX Health Solutions Inc (SRXH) reported diluted earnings per share of $-2.13 for fiscal year 2025. This represents a -2030.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

SRX Health Solutions Inc Financials

SRXH

Source SEC Filings (10-K/10-Q) Updated Feb 13, 2026 Currency USD FYE September

This page shows SRX Health Solutions Inc (SRXH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SRXH FY2025 2026-05-14

SRx Health’s recent pattern is a balance-sheet reset paired with a much smaller operating base that still consumes cash faster than it sells.

FY2025 looks far less balance-sheet-burdened than FY2024: total liabilities fell from $79.5M to $8.0M, which brought equity back above zero. But that cleanup did not restore operating self-funding; revenue was only $6.5M while operating cash outflow was -$8.1M, so the company became financially cleaner while its business engine became much smaller.

The sharp improvement seen in FY2024 was mostly an overhead story, not a scale story. In FY2025, gross profit was just $1.5M against SG&A of $12.9M, which means the cost structure now overwhelms the economics of each dollar sold.

Reported liquidity is better than the old solvency picture, but it is not highly liquid: the current ratio was 2.3x and cash was only $1.3M. With receivables and inventory carrying most current assets, near-term flexibility depends more on collections and stock turnover than on cash already sitting on hand.

Financial Health Signals

Financial Profile 25/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of SRX Health Solutions Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

SRX Health Solutions Inc has an operating margin of -174.6%, meaning the company retains $-175 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -17.1% the prior year.

Growth

SRX Health Solutions Inc's revenue declined 81.3% year-over-year, from $35.0M to $6.5M. This contraction results in a growth score of 0/100.

Leverage

100

SRX Health Solutions Inc carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

SRX Health Solutions Inc's current ratio of 2.29 indicates adequate short-term liquidity, earning a score of 42/100. The company can meet its near-term obligations, though with limited headroom.

Piotroski F-Score Weak

2/9

SRX Health Solutions Inc passes 2 of 9 financial strength tests. No profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Interest Coverage At Risk

-18.2x

SRX Health Solutions Inc earns $-18.2 in operating income for every $1 of interest expense (-$11.4M vs $628K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$6.5M

YoY-81.3%

5Y CAGR-31.3%

SRX Health Solutions Inc generated $6.5M in revenue in fiscal year 2025. This represents a decrease of 81.3% from the prior year.

EBITDA

-$11.4M

YoY-94.9%

SRX Health Solutions Inc's EBITDA was -$11.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 94.9% from the prior year.

Net Income

N/A

EPS (Diluted)

$-2.13

YoY-2030.0%

SRX Health Solutions Inc earned $-2.13 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 2030.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.3M

YoY-57.3%

5Y CAGR-19.7%

SRX Health Solutions Inc held $1.3M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

25M

YoY+1258.1%

SRX Health Solutions Inc had 25M shares outstanding in fiscal year 2025. This represents an increase of 1258.1% from the prior year.

Margins & Returns

Gross Margin

23.4%

YoY-13.8pp

5Y CAGR-14.5pp

SRX Health Solutions Inc's gross margin was 23.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 13.8 percentage points from the prior year.

Operating Margin

-174.6%

YoY-157.5pp

5Y CAGR-110.4pp

SRX Health Solutions Inc's operating margin was -174.6% in fiscal year 2025, reflecting core business profitability. This is down 157.5 percentage points from the prior year.

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

$137K

YoY-33.5%

SRX Health Solutions Inc spent $137K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 33.5% from the prior year.

Capital Expenditures

N/A

SRXH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$6.5M-81.3%	$35.0M-9.4%	$38.6M-29.4%	$54.7M+18.8%	$46.0M+8.0%	$42.6M
Cost of Revenue	$5.0M-77.2%	$22.0M-17.9%	$26.8M-32.0%	$39.4M+28.6%	$30.6M+15.7%	$26.5M
Gross Profit	$1.5M-88.3%	$13.0M+10.1%	$11.8M-22.7%	$15.3M-0.7%	$15.4M-4.6%	$16.1M
R&D Expenses	N/A	$100K0.0%	$100K-80.0%	$500K0.0%	$500K+400.0%	$100K
SG&A Expenses	$12.9M-31.8%	$19.0M-22.5%	$24.4M-31.0%	$35.4M+24.3%	$28.5M-17.3%	$34.5M
Operating Income	-$11.4M-91.2%	-$6.0M+71.8%	-$21.2M+45.4%	-$38.8M-124.5%	-$17.3M+36.8%	-$27.3M
Interest Expense	$628K+34.5%	$467K-65.5%	$1.4M+145.6%	$551K+117.1%	-$3.2M-135.0%	$9.2M
Income Tax	N/A	$9K+350.0%	$2K+111.1%	-$18K-148.6%	$37K	$0
Net Income	N/A	-$168K+99.3%	-$22.8M+42.1%	-$39.3M-1260.8%	$3.4M+105.7%	-$59.3M
EPS (Diluted)	$-2.13-2030.0%	$-0.10+99.7%	$-32.29+45.2%	$-58.93	$0.14	$-7.26

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$3K-99.9%	$2.8M	N/A	$11.4M+59.9%	$7.2M	N/A	$11.4M-73.3%	$42.7M
Cost of Revenue	$2K-99.9%	$1.8M	N/A	$8.0M+68.1%	$4.8M	N/A	$6.9M-79.4%	$33.3M
Gross Profit	$1K-99.9%	$1.1M	N/A	$3.4M+43.5%	$2.4M	N/A	$4.5M-52.0%	$9.4M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$5K-99.9%	$4.8M	N/A	$18.2M+422.9%	$3.5M	N/A	$5.6M-47.4%	$10.7M
Operating Income	$4K+100.1%	-$3.8M	N/A	-$17.4M-1501.3%	-$1.1M	N/A	-$1.1M+14.8%	-$1.3M
Interest Expense	$1K-99.9%	$1.3M	N/A	-$975K-1274.7%	$83K	N/A	$6K-96.7%	$180K
Income Tax	$4-99.9%	$4K	N/A	$138K+6800.0%	$2K	N/A	-$2K-100.6%	$345K
Net Income	$9K+100.1%	-$8.6M	N/A	-$15.1M-49.1%	-$10.1M-154.8%	-$4.0M-361.0%	$1.5M+149.0%	-$3.1M
EPS (Diluted)	$0.26+200.0%	$-0.26	N/A	$-0.74	$-0.39-129.4%	$-0.17-123.3%	$0.73+621.4%	$-0.14

SRXH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$8.4M-46.8%	$15.8M-5.6%	$16.7M-56.7%	$38.7M-48.2%	$74.7M+45.7%	$51.3M
Current Assets	$8.1M-45.8%	$15.0M-7.6%	$16.2M-41.0%	$27.5M-37.3%	$43.9M+150.1%	$17.6M
Cash & Equivalents	$1.3M-57.3%	$3.1M-31.2%	$4.5M+40.4%	$3.2M-85.4%	$21.7M+453.5%	$3.9M
Inventory	$2.1M-46.3%	$3.9M-41.5%	$6.6M-35.5%	$10.3M+95.6%	$5.2M+7.7%	$4.9M
Accounts Receivable	$3.9M-26.5%	$5.4M+23.4%	$4.4M-35.4%	$6.7M-0.7%	$6.8M+46.7%	$4.6M
Goodwill	N/A	$405K	N/A	$0-100.0%	$18.6M0.0%	$18.6M
Total Liabilities	$8.0M-89.9%	$79.5M+477.6%	$13.8M-19.8%	$17.1M+2.2%	$16.8M-78.8%	$79.4M
Current Liabilities	$3.5M-50.4%	$7.1M-47.8%	$13.7M+145.4%	$5.6M-24.0%	$7.3M-86.5%	$54.6M
Long-Term Debt	$0-100.0%	$2.4M-47.8%	$4.6M-59.6%	$11.4M+21.6%	$9.4M-61.7%	$24.6M
Total Equity	$407K+100.6%	-$63.7M-2260.6%	$2.9M-86.3%	$21.5M-62.8%	$57.9M+305.9%	-$28.1M
Retained Earnings	-$22.9M+92.9%	-$321.5M-0.1%	-$321.3M-7.6%	-$298.6M-15.2%	-$259.3M+0.5%	-$260.6M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$27K-99.9%	$27.1M+222.0%	$8.4M-75.3%	$34.0M+122.3%	$15.3M-3.2%	$15.8M-53.2%	$33.8M+158.0%	$13.1M
Current Assets	$19K-99.9%	$18.8M+131.8%	$8.1M-66.9%	$24.5M+68.8%	$14.5M-3.1%	$15.0M+10.0%	$13.6M+11.6%	$12.2M
Cash & Equivalents	$13K-99.9%	$13.1M+897.7%	$1.3M+43.5%	$912K-19.8%	$1.1M-62.9%	$3.1M+2792.5%	$106K-96.8%	$3.3M
Inventory	$1K-99.9%	$1.3M-36.6%	$2.1M-59.5%	$5.1M+13.7%	$4.5M+16.6%	$3.9M+14.8%	$3.4M-11.9%	$3.8M
Accounts Receivable	$3K-99.9%	$3.1M-22.5%	$3.9M-51.5%	$8.1M+70.6%	$4.8M-11.2%	$5.4M-42.1%	$9.3M+114.5%	$4.3M
Goodwill	N/A	N/A	N/A	N/A	$405K0.0%	$405K0.0%	$405K0.0%	$405K
Total Liabilities	$24K-99.9%	$23.5M+194.3%	$8.0M-90.0%	$79.9M+7.9%	$74.0M-6.9%	$79.5M-10.6%	$88.9M+155.6%	$34.8M
Current Liabilities	$24K-99.9%	$23.5M+564.1%	$3.5M-95.2%	$74.1M+912.5%	$7.3M+2.4%	$7.1M-91.2%	$81.3M+792.5%	$9.1M
Long-Term Debt	N/A	N/A	$0-100.0%	$1.9M	N/A	$2.4M+246.8%	$696K	N/A
Total Equity	$4K-99.9%	$3.5M+765.8%	$407K+100.9%	-$45.9M+21.9%	-$58.7M+7.8%	-$63.7M-15.5%	-$55.1M-154.2%	-$21.7M
Retained Earnings	$32K+100.1%	-$31.5M-37.6%	-$22.9M+76.7%	-$98.4M+69.5%	-$322.5M-0.3%	-$321.5M-359.1%	-$70.0M+78.2%	-$321.5M

SRXH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$8.1M-86.9%	-$4.4M-4591.8%	$97K+100.5%	-$20.6M-73.3%	-$11.9M-58.0%	-$7.5M
Capital Expenditures	N/A	$41K+127.8%	$18K-90.9%	$198K-43.9%	$353K+133.8%	$151K
Free Cash Flow	N/A	-$4.4M-5667.1%	$79K+100.4%	-$20.8M-69.9%	-$12.2M-59.5%	-$7.7M
Investing Cash Flow	$5.9M+362.2%	-$2.3M-12411.1%	-$18K+90.9%	-$198K+43.9%	-$353K-133.8%	-$151K
Financing Cash Flow	$12.2M+133.2%	$5.2M+202.4%	-$5.1M-497.6%	$1.3M-96.6%	$37.2M+307.9%	$9.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$137K-33.5%	$206K	N/A	$0-100.0%	$1.6M	$0

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$3K+100.1%	-$2.9M-138.4%	$7.6M+148.1%	-$15.8M-4218.8%	$384K-73.8%	$1.5M+166.4%	-$2.2M-11115.0%	$20K
Capital Expenditures	N/A	N/A	N/A	N/A	$7K-41.7%	$12K+9.1%	$11K-26.7%	$15K
Free Cash Flow	N/A	N/A	N/A	N/A	$377K-74.0%	$1.5M+165.5%	-$2.2M-44380.0%	$5K
Investing Cash Flow	$8K+100.1%	-$8.5M-14.7%	-$7.4M-176.9%	$9.6M+950.8%	-$1.1M-141.9%	$2.7M+284.3%	-$1.5M-9640.0%	-$15K
Financing Cash Flow	$23K-99.9%	$23.1M+156.5%	$9.0M+29.9%	$6.9M+685.3%	-$1.2M+66.6%	-$3.5M-169.4%	$5.1M+969.7%	-$588K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$0+100.0%	-$56K	N/A	N/A	N/A	N/A

SRXH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	23.4%-13.8pp	37.1%+6.6pp	30.6%+2.7pp	27.9%-5.5pp	33.4%-4.4pp	37.8%
Operating Margin	-174.6%-157.5pp	-17.1%+37.8pp	-54.9%+16.1pp	-71.0%-33.4pp	-37.6%+26.6pp	-64.1%
Net Margin	N/A	-0.5%+58.5pp	-59.0%+12.9pp	-71.9%-79.3pp	7.4%+146.7pp	-139.3%
Return on Equity	N/A	N/A	-772.6%-590.0pp	-182.6%-188.5pp	5.9%	N/A
Return on Assets	N/A	-1.1%+135.0pp	-136.1%-34.4pp	-101.6%-106.2pp	4.5%+120.3pp	-115.8%
Current Ratio	2.29+0.2	2.10+0.9	1.19-3.7	4.93-1.0	5.98+5.7	0.32
Debt-to-Equity	0.00+0.0	-0.04-1.6	1.57+1.0	0.53+0.4	0.16+1.0	-0.88
FCF Margin	N/A	-12.6%-12.8pp	0.2%+38.2pp	-38.0%-11.4pp	-26.5%-8.6pp	-18.0%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	37.5%0.0pp	37.5%	N/A	29.9%-3.4pp	33.3%	N/A	39.7%+17.7pp	22.1%
Operating Margin	135.0%+270.0pp	-135.0%	N/A	-152.2%-137.0pp	-15.2%	N/A	-9.9%-6.8pp	-3.1%
Net Margin	306.9%+613.8pp	-306.9%	N/A	-132.2%+9.6pp	-141.8%	N/A	13.4%+20.7pp	-7.3%
Return on Equity	244.4%+488.9pp	-244.4%	N/A	N/A	-12.1%	N/A	N/A	N/A
Return on Assets	31.8%+63.7pp	-31.8%	N/A	-44.5%+21.9pp	-66.4%-41.2pp	-25.2%-29.7pp	4.5%+28.3pp	-23.8%
Current Ratio	0.800.0	0.80-1.5	2.29+2.0	0.33-1.7	1.99-0.1	2.10+1.9	0.17-1.2	1.34
Debt-to-Equity	6.680.0	6.68+6.7	0.00+0.0	-0.04+1.2	-1.26-1.2	-0.04-0.0	-0.01+1.6	-1.60
FCF Margin	N/A	N/A	N/A	N/A	5.3%	N/A	-19.5%-19.5pp	0.0%

Similar Companies

Amer Shared Hosp AMS

$8.8M

Concord Medical CCM

$20.6M

NewGenIvf Group NIVF

$420K

Frequently Asked Questions

What is SRX Health Solutions Inc's annual revenue?

SRX Health Solutions Inc (SRXH) reported $6.5M in total revenue for fiscal year 2025. This represents a -81.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is SRX Health Solutions Inc's revenue growing?

SRX Health Solutions Inc (SRXH) revenue declined by 81.3% year-over-year, from $35.0M to $6.5M in fiscal year 2025.

What is SRX Health Solutions Inc's EBITDA?

SRX Health Solutions Inc (SRXH) had EBITDA of -$11.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does SRX Health Solutions Inc have?

As of fiscal year 2025, SRX Health Solutions Inc (SRXH) had $1.3M in cash and equivalents against $0 in long-term debt.

What is SRX Health Solutions Inc's gross margin?

SRX Health Solutions Inc (SRXH) had a gross margin of 23.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is SRX Health Solutions Inc's operating margin?

SRX Health Solutions Inc (SRXH) had an operating margin of -174.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is SRX Health Solutions Inc's operating cash flow?

SRX Health Solutions Inc (SRXH) generated -$8.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are SRX Health Solutions Inc's total assets?

SRX Health Solutions Inc (SRXH) had $8.4M in total assets as of fiscal year 2025, including both current and long-term assets.

Does SRX Health Solutions Inc buy back shares?

Yes, SRX Health Solutions Inc (SRXH) spent $137K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does SRX Health Solutions Inc have outstanding?

SRX Health Solutions Inc (SRXH) had 25M shares outstanding as of fiscal year 2025.

What is SRX Health Solutions Inc's current ratio?

SRX Health Solutions Inc (SRXH) had a current ratio of 2.29 as of fiscal year 2025, which is generally considered healthy.

What is SRX Health Solutions Inc's debt-to-equity ratio?

SRX Health Solutions Inc (SRXH) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is SRX Health Solutions Inc's cash runway?

Based on fiscal year 2025 data, SRX Health Solutions Inc (SRXH) had $1.3M in cash against an annual operating cash burn of $8.1M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is SRX Health Solutions Inc's Piotroski F-Score?

SRX Health Solutions Inc (SRXH) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Can SRX Health Solutions Inc cover its interest payments?

SRX Health Solutions Inc (SRXH) has an interest coverage ratio of -18.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is SRX Health Solutions Inc?

SRX Health Solutions Inc (SRXH) scores 25 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.